

Igor N Bondarenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5779919/publications.pdf>

Version: 2024-02-01

177
papers

39,555
citations

17440

63
h-index

5988

160
g-index

177
all docs

177
docs citations

177
times ranked

34150
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of Patients With Sickle Cell Disease and Trait After Congenital Heart Disease Surgery. <i>Annals of Thoracic Surgery</i> , 2023, 115, 1494-1502.	1.3	3
2	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study. <i>BioDrugs</i> , 2022, 36, 55-69.	4.6	7
3	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. <i>Cancers</i> , 2022, 14, 1168.	3.7	0
4	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 ⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	7.0	65
5	Durvalumab, with or without tremelimumab, plus platinum ⁺ etoposide versus platinum ⁺ etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65.	10.7	356
6	Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 327-327.	1.6	8
7	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. <i>Lancet</i> , The, 2021, 397, 592-604.	13.7	441
8	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 531-540.	2.6	15
9	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. <i>BioDrugs</i> , 2021, 35, 337-350.	4.6	21
10	Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 \geq 50%: Results from EMPOWER-Lung 1 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9078-9078.	1.6	3
11	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 678-689.	10.7	83
12	Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 369-377.	2.5	6
13	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). <i>BioDrugs</i> , 2021, 35, 417-428.	4.6	13
14	O11-5 Durvalumab(D) \pm tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN. <i>Annals of Oncology</i> , 2021, 32, S289.	1.2	0
15	Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. <i>Breast</i> , 2021, 58, 18-26.	2.2	3
16	Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive ⁺ stage small cell lung cancer: A multicentre, randomised, double ⁺ blind, placebo ⁺ controlled Phase \leq III \leq trial. <i>International Journal of Cancer</i> , 2021, 148, 2557-2570.	5.1	44
17	Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110458.	3.2	6
18	363 ⁺ ...KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1 ⁺ positive, locally advanced or metastatic non ⁺ small-cell lung cancer. , 2021, 9, A390-A390.		8

#	ARTICLE	IF	CITATIONS
19	A Phase III, Randomized, Multi-Center, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627, a Novel G-CSF, in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. <i>Blood</i> , 2021, 138, 4290-4290.	1.4	1
20	Significant Improvements in Mortality After the Fontan Operation in Children With Down Syndrome. <i>Annals of Thoracic Surgery</i> , 2020, 109, 835-841.	1.3	8
21	Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation- positive melanoma receiving adjuvant vemurafenib. <i>Annals of Oncology</i> , 2020, 31, 153-159.	1.2	25
22	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
23	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.	27.0	1,725
24	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e204429.	7.1	22
25	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 419-428.	2.5	73
26	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
27	A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 12-18.	2.0	21
28	Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. , 2020, , .		1
29	The Phantom for Studying Foreign Bodies- Echo-Signs. <i>International Journal of Biomedicine</i> , 2020, 10, 124-128.	0.2	4
30	Abstract OT1-08-07: CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane. , 2020, , .		0
31	Abstract OT1-08-08: CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC). , 2020, , .		0
32	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. <i>BioDrugs</i> , 2019, 33, 555-570.	4.6	36
33	Health-related quality of life in patients with fully resected BRAFV600 mutation- positive melanoma receiving adjuvant vemurafenib. <i>European Journal of Cancer</i> , 2019, 123, 155-161.	2.8	5
34	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2- positive breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 1-9.	2.8	39
35	Late Survival and Patient-Perceived Health Status of the Congenital Heart Surgeons- Society dextro-Transposition of the Great Arteries Cohort. <i>Annals of Thoracic Surgery</i> , 2019, 108, 1447-1455.	1.3	9
36	Durvalumab plus platinum- etoposide versus platinum- etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	13.7	1,274

#	ARTICLE	IF	CITATIONS
37	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
38	Efficacy and Safety Analysis of Nelinepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4248-4254.	7.0	129
39	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	13.7	2,347
40	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
41	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
42	Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. <i>BMC Cancer</i> , 2019, 19, 122.	2.6	6
43	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. <i>British Journal of Cancer</i> , 2019, 120, 172-182.	6.4	43
44	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1021-1021.	1.6	6
45	Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.. <i>Journal of Clinical Oncology</i> , 2019, 37, 580-580.	1.6	3
46	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600 mutant unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9507-9507.	1.6	8
47	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1107-TPS1107.	1.6	4
48	Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 16-16.	1.6	13
49	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 543-543.	1.6	11
50	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
51	A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. <i>European Journal of Cancer</i> , 2018, 93, 19-27.	2.8	58
52	Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. <i>Annals of Oncology</i> , 2018, 29, 1195-1202.	1.2	13
53	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 583-586.	2.5	49
54	Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. <i>Annals of Oncology</i> , 2018, 29, 154-161.	1.2	161

#	ARTICLE	IF	CITATIONS
55	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	27.0	3,530
56	Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 968-974.	1.6	78
57	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 845-855.	8.1	32
58	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	27.0	805
59	Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1548-1553.	1.2	30
60	Milestones over the development of SB3, a trastuzumab biosimilar. <i>Future Oncology</i> , 2018, 14, 2795-2803.	2.4	1
61	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 916-929.	10.7	131
62	A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 109-109.	1.6	1
63	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 110-110.	1.6	4
64	ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155). <i>Journal of Clinical Oncology</i> , 2018, 36, 5503-5503.	1.6	25
65	A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 9059-9059.	1.6	7
66	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tasetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1106-TPS1106.	1.6	1
67	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%: Open-label, phase 3 KEYNOTE-042 study. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA4-LBA4.	1.6	146
68	Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, e12631-e12631.	1.6	1
69	Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase II results from a head-to-head comparison with Pegfilgrastim (Peg). <i>Journal of Clinical Oncology</i> , 2018, 36, 2528-2528.	1.6	0
70	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies. <i>Journal of Clinical Oncology</i> , 2018, 36, 1060-1060.	1.6	2
71	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	1.2	549
72	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 37.	7.4	129

#	ARTICLE	IF	CITATIONS
73	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. <i>Supportive Care in Cancer</i> , 2017, 25, 1127-1135.	2.2	37
74	Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1467-1482.	10.7	265
75	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.	13.7	153
76	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse) "only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. <i>Gynecologic Oncology</i> , 2017, 146, 484-490.	1.4	81
77	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <i>Targeted Oncology</i> , 2017, 12, 475-485.	3.6	30
78	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. <i>European Journal of Cancer</i> , 2017, 70, 146-155.	2.8	108
79	Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. <i>Acta Oncol</i> ³ gica, 2017, 56, 441-447.	1.8	26
80	A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. <i>Annals of Oncology</i> , 2017, 28, 2142-2148.	1.2	30
81	Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1001-1001.	1.6	55
82	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 509-509.	1.6	11
83	Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14065-e14065.	1.6	1
84	ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5603-TPS5603.	1.6	2
85	Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10101-10101.	1.6	0
86	A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. <i>Oncologist</i> , 2016, 21, 7-15.	3.7	21
87	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	10.7	1,344
88	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	7.1	242
89	Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. <i>Supportive Care in Cancer</i> , 2016, 24, 4913-4920.	2.2	8
90	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2016, 388, 2997-3005.	13.7	435

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. <i>Breast Cancer Research</i> , 2016, 18, 67.	5.0	140
92	Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6002-6009.	7.0	20
93	A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2016, 27, 680-687.	1.2	40
94	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
95	A Randomized Phase II/III Study of Naptumomab Estafenatox + IFN γ versus IFN γ in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 3172-3181.	7.0	22
96	A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 1197-1207.	1.6	52
97	Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2016, 27, 106-113.	1.2	58
98	Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. <i>Supportive Care in Cancer</i> , 2016, 24, 267-273.	2.2	18
99	Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA503-LBA503.	1.6	4
100	Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA503-LBA503.	1.6	9
101	Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. <i>Medical Oncology</i> , 2015, 32, 623.	2.5	11
102	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
103	Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 339.	2.6	14
104	An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 92-99.	2.6	12
105	Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, 317-326.	2.8	58
106	Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 497-504.	1.2	56
107	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
108	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	1.6	445

#	ARTICLE	IF	CITATIONS
109	A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. <i>British Journal of Cancer</i> , 2015, 113, 1140-1147.	6.4	30
110	Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. <i>Lung Cancer</i> , 2015, 90, 267-273.	2.0	26
111	Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. <i>SpringerPlus</i> , 2015, 4, 316.	1.2	17
112	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). <i>Annals of Oncology</i> , 2015, 26, 1741-1748.	1.2	87
113	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 25-35.	10.7	1,574
114	Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4000-4000.	1.6	85
115	Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4015-4015.	1.6	56
116	Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4557-4557.	1.6	5
117	The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 572-572.	1.6	1
118	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEFERTT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-610.	1.6	3
119	Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy. , 2015, , .		0
120	Efficacy and safety of adding the retinoid tamibarotene or placebo to paclitaxel/carboplatin for advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19034-e19034.	1.6	0
121	Repair of Anomalous Aortic Origin of a Coronary Artery in 113 Patients. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2014, 5, 507-514.	0.8	60
122	A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. <i>Annals of Oncology</i> , 2014, 25, 1328-1333.	1.2	202
123	Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. <i>Annals of Oncology</i> , 2014, 25, 1340-1346.	1.2	187
124	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt337-djt337.	6.3	218
125	Anomalous Aortic Origin of a Coronary Artery. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2014, 5, 22-30.	0.8	91
126	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 143-155.	10.7	823

#	ARTICLE	IF	CITATIONS
127	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
128	A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). <i>Annals of Oncology</i> , 2014, 25, 824-831.	1.2	112
129	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 290.	2.6	46
130	An Unusual Complication of Three-Patch Repair of Supravalvar Aortic Stenosis. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1449-1451.	1.3	4
131	Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. <i>Clinical Breast Cancer</i> , 2014, 14, 101-108.	2.4	21
132	A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. <i>Blood</i> , 2014, 124, 1584-1584.	1.4	3
133	Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1013-1013.	1.6	1
134	Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor- α positive (ER+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 519-519.	1.6	4
135	Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8091-8091.	1.6	2
136	Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8100-8100.	1.6	2
137	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8529-8529.	1.6	5
138	Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8118-TPS8118.	1.6	6
139	Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4029-4029.	1.6	0
140	Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).. <i>Journal of Clinical Oncology</i> , 2014, 32, 520-520.	1.6	0
141	Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. <i>Journal of Clinical Oncology</i> , 2013, 31, 4453-4461.	1.6	147
142	Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. <i>BMC Cancer</i> , 2013, 13, 386.	2.6	75
143	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. <i>Annals of Oncology</i> , 2013, 24, 75-83.	1.2	567
144	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temozolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 195-202.	1.6	252

#	ARTICLE	IF	CITATIONS
145	PO120 FACTORS AFFECTING CHANGES IN IMMUNOHISTOCHEMISTRY PHENOTYPE OF BREAST CANCER. <i>Breast</i> , 2013, 22, S60.	2.2	0
146	Long-term functional health status and exercise test variables for patients with pulmonary atresia with intact ventricular septum: A Congenital Heart Surgeons Society study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 1018-1027.e3.	0.8	47
147	Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 1985-1993.	6.4	74
148	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.	1.6	388
149	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 149-155.	2.5	16
150	Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. <i>Investigational New Drugs</i> , 2013, 31, 1283-1293.	2.6	48
151	Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1341-1347.	1.6	122
152	A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).. <i>Journal of Clinical Oncology</i> , 2013, 31, CRA8007-CRA8007.	1.6	12
153	Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim. <i>Blood</i> , 2013, 122, 4856-4856.	1.4	0
154	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 921-929.	1.6	244
155	Usefulness of CT for diagnosis of breast malignancy metastasis variants to the vertebrae. <i>Przegląd Menopauzalny</i> , 2012, 6, 441-444.	1.3	0
156	Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 610-617.	1.2	82
157	Iplimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2046-2054.	1.6	931
158	Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2055-2062.	1.6	676
159	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). <i>Journal of Clinical Oncology</i> , 2012, 30, 3588-3595.	1.6	194
160	Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4501-4501.	1.6	40
161	A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7551-7551.	1.6	1
162	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7558-7558.	1.6	6

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.. Journal of Clinical Oncology, 2012, 30, 9125-9125.	1.6	4
164	Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.. Journal of Clinical Oncology, 2012, 30, e19587-e19587.	1.6	1
165	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology, 2011, 22, 1535-1546.	1.2	696
166	RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative, Locally Recurrent or Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 1252-1260.	1.6	932
167	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	27.0	4,074
168	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2011, 12, 795-805.	10.7	199
169	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. Breast, 2011, 20, S45.	2.2	0
170	Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptorâ€“Positive Locally Advanced or Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 6822-6830.	7.0	63
171	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptorâ€“Positive Advanced Breast Cancer. Journal of Clinical Oncology, 2010, 28, 4594-4600.	1.6	553
172	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology, 2010, 21, 1712-1717.	1.2	468
173	A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Current Medical Research and Opinion, 2010, 26, 2339-2346.	1.9	51
174	Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study. Journal of Clinical Oncology, 2009, 27, 4522-4529.	1.6	97
175	Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 663-671.	1.6	1,524
176	Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 728-734.	1.1	126
177	Phase III, Double-Blind, Controlled Trial of Atamestane Plus Toremifene Compared With Letrozole in Postmenopausal Women With Advanced Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 2007, 25, 4961-4966.	1.6	21